Related Experiment Video
Updated: Aug 11, 2025
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Martin Sattler1, Atish Mohanty2, Prakash Kulkarni2
1Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Novel inhibitors targeting Kirsten rat sarcoma virus homolog (KRAS) KRASG12C in various cancers have shown good initial efficacy, but therapy-related drug resistance eventually occurs in most patients. It has become apparent that cancer cells not only rely on novel mutations that provide escape mechanisms, but about half of them become resistant in the absence of apparent genetic mutations. Redundancies within the KRAS signaling pathways and cross-talk between these pathways - as well as other canonical cancer-driving mechanisms - not only provide challenges but also present opportunities for drug development and targeted approaches. We discuss the challenges for the duality of KRAS inhibitor drug resistance with an additional focus on nongenetic mechanisms and the potential for patient-centered combination treatments.
Insights
New KRASG12C inhibitors show promise but face drug resistance. Understanding both genetic and non-genetic resistance mechanisms is key for developing effective combination therapies against cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapies for Kirsten rat sarcoma virus homolog (KRAS) G12C mutations show initial efficacy in various cancers.
- Therapy-related drug resistance is a significant clinical challenge, observed in most patients treated with KRAS inhibitors.
- Resistance mechanisms include novel genetic mutations and non-genetic adaptations in cancer cells.
Purpose of the Study:
- To discuss the challenges associated with drug resistance in KRAS G12C-targeted therapies.
- To explore the role of non-genetic mechanisms in the development of resistance.
- To identify opportunities for developing patient-centered combination treatments.
Main Methods:
- Review of current literature on KRAS G12C inhibitors and drug resistance.
- Analysis of signaling pathway redundancies and cross-talk in cancer.
- Discussion of potential combination therapeutic strategies.
Main Results:
- KRAS G12C inhibitors face eventual drug resistance in a majority of patients.
- Approximately half of resistance cases occur without identifiable genetic mutations, suggesting non-genetic drivers.
- Complexities in KRAS signaling pathways and interactions present both challenges and opportunities.
Conclusions:
- Addressing both genetic and non-genetic resistance mechanisms is crucial for overcoming therapeutic limitations.
- Combination therapies targeting KRAS pathways and other cancer drivers may improve patient outcomes.
- Further research into non-genetic resistance is warranted for developing novel treatment strategies.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers